🇺🇸 Linagliptin and Metformin in United States

3 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diabetic Ketoacidosis — 1 report (33.33%)
  2. Hypoglycaemia — 1 report (33.33%)
  3. Pancreatitis — 1 report (33.33%)

Source database →

Linagliptin and Metformin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Linagliptin and Metformin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Linagliptin and Metformin in United States?

Zhujiang Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.